Patient Preferences Belong in Protocol Design.

A protocol can be scientifically rigorous and behaviorally impossible. Patient input reveals that difference before recruitment pays for it.

Preference is data about feasibility.

Patients are experts in the lived experience of a condition. They know which symptoms dominate daily life, which treatment effects matter, which burdens feel tolerable, and which visit demands collide with work, family, mobility, or caregiving.

FDA's patient-focused drug development program encourages systematic use of patient and caregiver input in development and decision-making. This is more than a listening exercise. It can inform endpoints, tradeoffs, recruitment practices, and the acceptability of participation burden.

Ask before the protocol becomes expensive.

Input gathered after launch can improve communication and support, but it cannot easily repair an unnecessary procedure, unrealistic schedule, inaccessible site model, or endpoint that patients do not recognize as meaningful.

Early engagement should test the assumptions underneath the design. Which visits require the greatest effort? What does recovery look like? Who else is affected by participation? What would make a procedure unacceptable? Where can flexibility be added without compromising scientific integrity?

The loudest voice is not the population.

Advisory input must reflect the people the study intends to enroll, including variation in disease severity, geography, language, age, access, caregiving, digital confidence, and prior research experience. A convenient panel may produce confident recommendations that fail outside its own context.

Teams should document who participated, which perspectives were absent, what changed, and why. When input cannot be incorporated, the tradeoff should be explicit. Transparency turns engagement from performance into accountable design.

Patient input should leave a design trail.

Meaningful engagement changes something: visit timing, remote options, endpoint selection, reimbursement, communication sequencing, caregiver support, eligibility, or the way uncertainty is explained. Those changes should be linked to the readiness condition they address.

The outcome is not a protocol that satisfies every preference. That is rarely possible. The outcome is a design that understands its human tradeoffs and prepares the populations affected by them.

Sources.

1. FDA, Patient-Focused Drug Development
2. CTTI, Patient Engagement Resources
3. CTTI, Patient Group Engagement Recommendations
4. Preference Effects in Randomized Clinical Trials, Systematic Review

About the author

Rebecca Schelkun

Vice President, Patient Readiness

Rebecca is Vice President of Patient Readiness at Jumo Health. She combines public health expertise in epidemiology and biostatistics with experience across health equity, patient advocacy, pediatrics, rare disease, and clinical trial strategy. At Jumo, she turns protocol demands and lived experience into education, decision support, and expectation alignment patients can use.